1. Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N, Kato J, Kobayashi K, Kobayashi K, Koganei K, Kunisaki R, Motoya S, Nagahori M, Nakase H, Omata F, Saruta M, Watanabe T, Tanaka T, Kanai T, Noguchi Y, Takahashi KI, Watanabe K, Hibi T, Suzuki Y, Watanabe M, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol 53 (3):305-353. doi:10.1007/s00535-018-1439-1,2018.
2. Murakami Y, Nishiwaki Y, Oba MS, Asakura K, Ohfuji S, Fukushima W, Suzuki Y, Nakamura Y. Estimated prevalence of ulcerative colitis and Crohn's disease in Japan in 2014: an analysis of a nationwide survey. J Gastroenterol. doi:10.1007/s00535-019- 01603-8,2019.
3. 潰瘍性大腸炎・クローン病診断基準・治療指針「難治性炎症性腸管障害に関する 調査研究」(鈴木班)平成 29 年度総括・分担研究報告書.
4. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 448 (7152):427-434. doi:10.1038/nature06005,2007.
5. Sandborn WJ, Su C, Sands BE, D'Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W, Friedman G, Lawendy N, Yu D, Woodworth D, Mukherjee A, Zhang H, Healey P, Panes J, Octave Induction OI, Investigators OS. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 376 (18):1723-1736. doi:10.1056/NEJMoa1606910,2017.
6. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A, Group GS. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 369 (8):699-710. doi:10.1056/NEJMoa1215734,2013.
7. Leijonmarck CE, Persson PG, Hellers G. Factors affecting colectomy rate in ulcerative colitis: an epidemiologic study. Gut 31 (3):329-333,1990.
8. Chow DK, Leong RW, Tsoi KK, Ng SS, Leung WK, Wu JC, Wong VW, Chan FK, Sung JJ. Long-term follow-up of ulcerative colitis in the Chinese population. Am J Gastroenterol 104 (3):647-654. doi:10.1038/ajg.2008.74,2009.
9. Moore SE, McGrail KM, Peterson S, Raval MJ, Karimuddin AA, Phang PT, Bressler B, Brown CJ. Infliximab in ulcerative colitis: the impact of preoperative treatment on rates of colectomy and prescribing practices in the province of British Columbia, Canada. Dis Colon Rectum 57 (1):83-90. doi:10.1097/DCR.0000000000000003,2014.
10. Aylett SO. Conservative surgery in the treatment of ulcerative colitis. Br Med J 2 (4850):1348-1351. doi:10.1136/bmj.2.4850.1348,1953.
11. Parks AG, Nicholls RJ. Proctocolectomy without ileostomy for ulcerative colitis. Br Med J 2 (6130):85-88. doi:10.1136/bmj.2.6130.85,1978.
12. Utsunomiya J, Yamamura T, Kusunoki M, Natori H, Fujimoto Y, Shoji Y, Iwama T. J-pouch: change of a method over years. Z Gastroenterol Verh 24:249-251,1989.
13. Bach SP, Mortensen NJ. Ileal pouch surgery for ulcerative colitis. World J Gastroenterol 13 (24):3288-3300,2007.
14. Mege D, Figueiredo MN, Manceau G, Maggiori L, Bouhnik Y, Panis Y. Threestage Laparoscopic Ileal Pouch-anal Anastomosis Is the Best Approach for High-risk Patients with Inflammatory Bowel Disease: An Analysis of 185 Consecutive Patients. J Crohns Colitis 10 (8):898-904. doi:10.1093/ecco-jcc/jjw040,2016.
15. Ikeuchi H, Nakano H, Uchino M, Nakamura M, Noda M, Yanagi H, Yamamura T. Safety of one-stage restorative proctocolectomy for ulcerative colitis. Dis Colon Rectum 48 (8):1550-1555. doi:10.1007/s10350-005-0083-z,2005.
16. Davies M, Hawley PR. Ten years experience of one-stage restorative proctocolectomy for ulcerative colitis. Int J Colorectal Dis 22 (10):1255-1260. doi:10.1007/s00384-006-0243-1,2007.
17. Mege D, Colombo F, Stellingwerf ME, Germain A, Maggiori L, Foschi D, Buskens CJ, de Buck van Overstraeten A, Sampietro G, D'Hoore A, Bemelman W, Panis Y. Risk Factors for Small Bowel Obstruction After Laparoscopic Ileal Pouch-Anal Anastomosis for Inflammatory Bowel Disease: A Multivariate Analysis in Four Expert Centres in Europe. J Crohns Colitis 13 (3):294-301. doi:10.1093/ecco-jcc/jjy160,2019.
18. Goligher JC, Hoffman DC, de Dombal FT. Surgical treatment of severe attacks of ulcerative colitis, with special reference to the advantages of early operation. Br Med J 4 (5737):703-706. doi:10.1136/bmj.4.5737.703,1970.
19. Alves A, Panis Y, Bouhnik Y, Maylin V, Lavergne-Slove A, Valleur P. Subtotal colectomy for severe acute colitis: a 20-year experience of a tertiary care center with an aggressive and early surgical policy. J Am Coll Surg 197 (3):379-385. doi:10.1016/S1072-7515(03)00434-4,2003.
20. Fazio VW, Kiran RP, Remzi FH, Coffey JC, Heneghan HM, Kirat HT, Manilich E, Shen B, Martin ST. Ileal pouch anal anastomosis: analysis of outcome and quality of life in 3707 patients. Ann Surg 257 (4):679-685. doi:10.1097/SLA.0b013e31827d99a2,2013.
21. Okada S, Hata K, Yokoyama T, Sasaki K, Kawai K, Tanaka T, Nishikawa T, Otani K, Kaneko M, Murono K, Emoto S, Nozawa H. Postoperative bleeding after subtotal colectomy in two patients with severe ulcerative colitis. J Dig Dis 19 (10):641-645. doi:10.1111/1751-2980.12658,2018.
22. Marcello PW, Roberts PL, Schoetz DJ, Jr., Coller JA, Murray JJ, Veidenheimer MC. Obstruction after ileal pouch-anal anastomosis: a preventable complication? Dis Colon Rectum 36 (12):1105-1111,1993.
23. Francois Y, Dozois RR, Kelly KA, Beart RW, Jr., Wolff BG, Pemberton JH, Ilstrup DM. Small intestinal obstruction complicating ileal pouch-anal anastomosis. Ann Surg 209 (1):46-50,1989.
24. Dolejs S, Kennedy G, Heise CP. Small bowel obstruction following restorative proctocolectomy: affected by a laparoscopic approach? J Surg Res 170 (2):202-208. doi:10.1016/j.jss.2011.03.004,2011.
25. Dafnis G. Early and late surgical outcomes of ileal pouch-anal anastomosis within a defined population in Sweden. Eur J Gastroenterol Hepatol 28 (7):842-849. doi:10.1097/MEG.0000000000000618,2016.
26. Mizushima T Kameyama H, Watanabe K Risk factors of small bowel obstruction following total proctocolectomy and ileal pouch anal anastomosis with diverting loopileostomy for ulcerative colitis. Ann Gastroenterol Surg 1 (2):122–128,2017.
27. Ishii H, Hata K, Kishikawa J, Anzai H, Otani K, Yasuda K, Nishikawa T, Tanaka T, Tanaka J, Kiyomatsu T, Kawai K, Nozawa H, Kazama S, Yamaguchi H, Ishihara S, Sunami E, Kitayama J, Watanabe T. Incidence of neoplasias and effectiveness of postoperative surveillance endoscopy for patients with ulcerative colitis: comparison of ileorectal anastomosis and ileal pouch-anal anastomosis. World J Surg Oncol 14:75. doi:10.1186/s12957-016-0833-5,2016.
28. Kameyama H, Hashimoto Y, Shimada Y, Yamada S, Yagi R, Tajima Y, Okamura T, Nakano M, Miura K, Nagahashi M, Sakata J, Kobayashi T, Kosugi SI, Wakai T. Small Bowel Obstruction After Ileal Pouch-Anal Anastomosis With a Loop Ileostomy in Patients With Ulcerative Colitis. Ann Coloproctol 34 (2):94-100. doi:10.3393/ac.2017.06.14,2018.
29. MacLean AR, Cohen Z, MacRae HM, O'Connor BI, Mukraj D, Kennedy ED, Parkes R, McLeod RS. Risk of small bowel obstruction after the ileal pouch-anal anastomosis. Ann Surg 235 (2):200-206,2002.
30. Oliveira L, Reissman P, Nogueras J, Wexner SD. Laparoscopic creation of stomas. Surg Endosc 11 (1):19-23. doi:10.1007/s004649900287,1997.
31. Ritchie JK. Ulcerative colitis treated by ileostomy and excisional surgery. Fifteen years' experience at St. Mark's Hospital. Br J Surg 59 (5):345-351. doi:10.1002/bjs.1800590504,1972
32. 松岡宏樹 池内浩基, 中埜廣樹. 潰瘍性大腸炎患者 stoma 関連性合併症の検 討. 日本外科学会誌 109 (397),2008.
33. Fujii T, Morita H, Sutoh T, Yajima R, Tsutsumi S, Asao T, Kuwano H. Outlet Obstruction of Temporary Loop Diverting Ileostomy. Hepatogastroenterology 62 (139):602-605,2015.
34. Gao XH, Li JQ, Khan F, Chouhan H, Yu GY, Remer E, Stocchi L, Hull TL, Shen B. Difference in the frequency of pouchitis between ulcerative colitis and familial adenomatous polyposis: is the explanation in peripouch fat? Colorectal Dis 21 (9):1032- 1044. doi:10.1111/codi.14651,2019.
35. Shen B, Achkar JP, Lashner BA, Ormsby AH, Remzi FH, Bevins CL, Brzezinski A, Petras RE, Fazio VW. Endoscopic and histologic evaluation together with symptom assessment are required to diagnose pouchitis. Gastroenterology 121 (2):261-267. doi:10.1053/gast.2001.26290,2001.
36. Sandborn WJ, Tremaine WJ, Batts KP, Pemberton JH, Phillips SF. Pouchitis after ileal pouch-anal anastomosis: a Pouchitis Disease Activity Index. Mayo Clin Proc 69 (5):409-415. doi:10.1016/s0025-6196(12)61634-6,1994.
37. Shen B, Achkar JP, Connor JT, Ormsby AH, Remzi FH, Bevins CL, Brzezinski A, Bambrick ML, Fazio VW, Lashner BA. Modified pouchitis disease activity index: a simplified approach to the diagnosis of pouchitis. Dis Colon Rectum 46 (6):748-753. doi:10.1097/01.DCR.0000070528.00563.D9,2003.
38. Hata K, Ishihara S, Nozawa H, Kawai K, Kiyomatsu T, Tanaka T, Kishikawa J, Anzai H, Watanabe T. Pouchitis after ileal pouch-anal anastomosis in ulcerative colitis: Diagnosis, management, risk factors, and incidence. Dig Endosc 29 (1):26-34. doi:10.1111/den.12744,2017.
39. Bach SP, Mortensen NJ. Revolution and evolution: 30 years of ileoanal pouch surgery. Inflamm Bowel Dis 12 (2):131-145. doi:10.1097/01.MIB.0000197547.80558.59,2006.
40. Sehgal R, Berg A, Polinski JI, Hegarty JP, Lin Z, McKenna KJ, Stewart DB, Poritz LS, Koltun WA. Genetic risk profiling and gene signature modeling to predict risk of complications after IPAA. Dis Colon Rectum 55 (3):239-248. doi:10.1097/DCR.0b013e31823e2d18,2012.
41. Tyler AD, Milgrom R, Stempak JM, Xu W, Brumell JH, Muise AM, Sehgal R, Cohen Z, Koltun W, Shen B, Silverberg MS. The NOD2insC polymorphism is associated with worse outcome following ileal pouch-anal anastomosis for ulcerative colitis. Gut 62 (10):1433-1439. doi:10.1136/gutjnl-2011-301957,2013.
42. Yamazaki K, Takazoe M, Tanaka T, Kazumori T, Nakamura Y. Absence of mutation in the NOD2/CARD15 gene among 483 Japanese patients with Crohn's disease. J Hum Genet 47 (9):469-472. doi:10.1007/s100380200067,2002.
43. Inoue N, Tamura K, Kinouchi Y, Fukuda Y, Takahashi S, Ogura Y, Inohara N, Nunez G, Kishi Y, Koike Y, Shimosegawa T, Shimoyama T, Hibi T. Lack of common NOD2 variants in Japanese patients with Crohn's disease. Gastroenterology 123 (1):86- 91,2002.
44. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48 (4):526-535. doi:10.1136/gut.48.4.526,2001.
45. Uchino M, Ikeuchi H, Hata K, Okada S, Ishihara S, Morimoto K, Sahara R, Watanabe K, Fukushima K, Takahashi K, Kimura H, Hirata K, Mizushima T, Araki T, Kusunoki M, Nezu R, Nakao S, Itabashi M, Hirata A, Ozawa H, Ishida T, Okabayashi K, Yamamoto T, Noake T, Arakaki J, Watadani Y, Ohge H, Futatsuki R, Koganei K, Sugita A, Higashi D, Futami K. Changes in the rate of and trends in colectomy for ulcerative colitis during the era of biologics and calcineurin inhibitors based on a Japanese nationwide cohort study. Surg Today. doi:10.1007/s00595-019-01845-2,2019.
46. Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, Burisch J, Gecse KB, Hart AL, Hindryckx P, Langner C, Limdi JK, Pellino G, Zagorowicz E, Raine T, Harbord M, Rieder F, European Cs, Colitis O. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis 11 (6):649-670. doi:10.1093/ecco-jcc/jjx008,2017.
47. Li H, Jin Z, Li X, Wu L, Jin J. Associations between single-nucleotide polymorphisms and inflammatory bowel disease-associated colorectal cancers in inflammatory bowel disease patients: a meta-analysis. Clin Transl Oncol 19 (8):1018- 1027. doi:10.1007/s12094-017-1634-1,2017.
48. 宗像 慎也 河雅, 嵩原 一裕, 田代 良彦, 石山 隼, 杉本 起一, 小島 豊, 五 藤 倫敏, 冨木 裕一, 坂本 一博. 回腸瘻を造設した直腸癌症例における術後 Outlet obstruction の検討. 日本外科系連合学会誌 40 (1):20-24,2015.
49. Okita Y, Araki T, Kondo S, Fujikawa H, Yoshiyama S, Hiro J, Inoue M, Toiyama Y, Kobayashi M, Ohi M, Inoue Y, Uchida K, Mohri Y, Kusunoki M. Clinical Characteristics of Stoma-Related Obstruction after Ileal Pouch-Anal Anastomosis for Ulcerative Colitis. J Gastrointest Surg 21 (3):554-559. doi:10.1007/s11605-016-3329- 2,2017.
50. Cox MR, Gunn IF, Eastman MC, Hunt RF, Heinz AW. The operative aetiology and types of adhesions causing small bowel obstruction. Aust N Z J Surg 63 (11):848-852. doi:10.1111/j.1445-2197.1993.tb00358.x,1993.
51. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 48 (3):452-458. doi:10.1038/bmt.2012.244,2013.
52. Okada S, Hata K, Emoto S, Murono K, Kaneko M, Sasaki K, Otani K, Nishikawa T, Tanaka T, Kawai K, Nozawa H. Elevated risk of stoma outlet obstruction following colorectal surgery in patients undergoing ileal pouch-anal anastomosis: a retrospective cohort study. Surg Today 48 (12):1060-1067. doi:10.1007/s00595-018-1698-8,2018.
53. Aberg H, Pahlman L, Karlbom U. Small-bowel obstruction after restorative proctocolectomy in patients with ulcerative colitis. Int J Colorectal Dis 22 (6):637-642. doi:10.1007/s00384-006-0215-5,2007.
54. 内野 基, 池内浩基, 坂東 俊宏, 松岡 宏樹, 松本 譽之, 竹末 芳生, 冨田 尚 裕. Loop ileostomy 造設の工夫と outlet obstruction 予防効果. 日本大腸肛門病会 誌 64 (2):73-77,2011.
55. Fasth S, Hulten L. Loop ileostomy: a superior diverting stoma in colorectal surgery. World J Surg 8 (3):401-407,1984.
56. Winslet MC, Drolc Z, Allan A, Keighley MR. Assessment of the defunctioning efficiency of the loop ileostomy. Dis Colon Rectum 34 (8):699-703,1991.
57. Heuschen UA, Hinz U, Allemeyer EH, Lucas M, Heuschen G, Herfarth C. One- or two-stage procedure for restorative proctocolectomy: rationale for a surgical strategy in ulcerative colitis. Ann Surg 234 (6):788-794. doi:10.1097/00000658-200112000- 00010,2001.
58. Zittan E, Wong-Chong N, Ma GW, McLeod RS, Silverberg MS, Cohen Z. Modified Two-stage Ileal Pouch-Anal Anastomosis Results in Lower Rate of Anastomotic Leak Compared with Traditional Two-stage Surgery for Ulcerative Colitis. J Crohns Colitis 10 (7):766-772. doi:10.1093/ecco-jcc/jjw069,2016.
59. Hata K, Ishii H, Anzai H, Ishihara S, Nozawa H, Kawai K, Kiyomatsu T, Watanabe T. Preoperative Extraintestinal Manifestations Associated with Chronic Pouchitis in Japanese Patients with Ulcerative Colitis After Ileal Pouch-anal Anastomosis: A Retrospective Study. Inflamm Bowel Dis 23 (6):1019-1024. doi:10.1097/MIB.0000000000001094,2017.
60. Yamazaki K, McGovern D, Ragoussis J, Paolucci M, Butler H, Jewell D, Cardon L, Takazoe M, Tanaka T, Ichimori T, Saito S, Sekine A, Iida A, Takahashi A, Tsunoda T, Lathrop M, Nakamura Y. Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease. Hum Mol Genet 14 (22):3499-3506. doi:10.1093/hmg/ddi379,2005.
61. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nunez G, Cho JH. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411 (6837):603-606. doi:10.1038/35079114,2001.
62. Shen B. Acute and chronic pouchitis--pathogenesis, diagnosis and treatment. Nat Rev Gastroenterol Hepatol 9 (6):323-333. doi:10.1038/nrgastro.2012.58,2012.
63. Arimura Y, Isshiki H, Onodera K, Nagaishi K, Yamashita K, Sonoda T, Matsumoto T, Takahashi A, Takazoe M, Yamazaki K, Kubo M, Fujimiya M, Imai K, Shinomura Y. Characteristics of Japanese inflammatory bowel disease susceptibility loci. J Gastroenterol 49 (8):1217-1230. doi:10.1007/s00535-013-0866-2,2014.
64. Fuyuno Y, Yamazaki K, Takahashi A, Esaki M, Kawaguchi T, Takazoe M, Matsumoto T, Matsui T, Tanaka H, Motoya S, Suzuki Y, Kiyohara Y, Kitazono T, Kubo M. Genetic characteristics of inflammatory bowel disease in a Japanese population. J Gastroenterol 51 (7):672-681. doi:10.1007/s00535-015-1135-3,2016.
65. Kakuta Y, Kinouchi Y, Negoro K, Takahashi S, Shimosegawa T. Association study of TNFSF15 polymorphisms in Japanese patients with inflammatory bowel disease. Gut 55 (10):1527-1528. doi:10.1136/gut.2006.100297,2006.
66. Asano K, Matsushita T, Umeno J, Hosono N, Takahashi A, Kawaguchi T, Matsumoto T, Matsui T, Kakuta Y, Kinouchi Y, Shimosegawa T, Hosokawa M, Arimura Y, Shinomura Y, Kiyohara Y, Tsunoda T, Kamatani N, Iida M, Nakamura Y, Kubo M. A genome-wide association study identifies three new susceptibility loci for ulcerative colitis in the Japanese population. Nat Genet 41 (12):1325-1329. doi:10.1038/ng.482,2009.
67. Yamazaki K, Umeno J, Takahashi A, Hirano A, Johnson TA, Kumasaka N, Morizono T, Hosono N, Kawaguchi T, Takazoe M, Yamada T, Suzuki Y, Tanaka H, Motoya S, Hosokawa M, Arimura Y, Shinomura Y, Matsui T, Matsumoto T, Iida M, Tsunoda T, Nakamura Y, Kamatani N, Kubo M. A genome-wide association study identifies 2 susceptibility Loci for Crohn's disease in a Japanese population. Gastroenterology 144 (4):781-788. doi:10.1053/j.gastro.2012.12.021,2013.
68. Hirano A, Yamazaki K, Umeno J, Ashikawa K, Aoki M, Matsumoto T, Nakamura S, Ninomiya T, Matsui T, Hirai F, Kawaguchi T, Takazoe M, Tanaka H, Motoya S, Kiyohara Y, Kitazono T, Nakamura Y, Kamatani N, Kubo M. Association study of 71 European Crohn's disease susceptibility loci in a Japanese population. Inflamm Bowel Dis 19 (3):526-533. doi:10.1097/MIB.0b013e31828075e7,2013.
69. Muro M, Mrowiec A. Interleukin (IL)-1 Gene Cluster in Inflammatory Bowel Disease: Is IL-1RA Implicated in the Disease Onset and Outcome? Dig Dis Sci 60 (5):1126-1128. doi:10.1007/s10620-015-3571-6,2015.
70. Arend WP. Interleukin-1 receptor antagonist. Adv Immunol 54:167-227. doi:10.1016/s0065-2776(08)60535-0,1993.
71. Ponomarenko MP, Arkova O, Rasskazov D, Ponomarenko P, Savinkova L, Kolchanov N. Candidate SNP Markers of Gender-Biased Autoimmune Complications of Monogenic Diseases Are Predicted by a Significant Change in the Affinity of TATA- Binding Protein for Human Gene Promoters. Front Immunol 7:130. doi:10.3389/fimmu.2016.00130,2016.
72. Hayashi F, Watanabe M, Nanba T, Inoue N, Akamizu T, Iwatani Y. Association of the -31C/T functional polymorphism in the interleukin-1beta gene with the intractability of Graves' disease and the proportion of T helper type 17 cells. Clin Exp Immunol 158 (3):281-286. doi:10.1111/j.1365-2249.2009.04034.x,2009.
73. Loft ND, Skov L, Iversen L, Gniadecki R, Dam TN, Brandslund I, Hoffmann HJ, Andersen MR, Dessau RB, Bergmann AC, Andersen NM, Andersen PS, Bank S, Vogel U, Andersen V. Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis. Pharmacogenomics J 18 (3):494- 500. doi:10.1038/tpj.2017.31,2018.
74. Nyboe Andersen N, Pasternak B, Friis-Moller N, Andersson M, Jess T. Association between tumour necrosis factor-alpha inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study. BMJ 350:h2809. doi:10.1136/bmj.h2809,2015.
75. Gionchetti P, Campieri M, Belluzzi A, Bertinelli E, Ferretti M, Brignola C, Poggioli G, Miglioli M, Barbara L. Mucosal concentrations of interleukin-1 beta, interleukin-6, interleukin-8, and tumor necrosis factor-alpha in pelvic ileal pouches. Dig Dis Sci 39 (7):1525-1531,1994.
76. Schmidt C, Giese T, Ludwig B, Menges M, Schilling M, Meuer SC, Zeuzem S, Stallmach A. Increased cytokine transcripts in pouchitis reflect the degree of inflammation but not the underlying entity. Int J Colorectal Dis 21 (5):419-426. doi:10.1007/s00384-005-0024-2,2006.
77. Patel RT, Bain I, Youngs D, Keighley MR. Cytokine production in pouchitis is similar to that in ulcerative colitis. Dis Colon Rectum 38 (8):831-837,1995.
78. Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 140 (6):1756-1767. doi:10.1053/j.gastro.2011.02.016,2011.
79. Brett PM, Yasuda N, Yiannakou JY, Herbst F, Ellis HJ, Vaughan R, Nicholls RJ, Ciclitira PJ. Genetic and immunological markers in pouchitis. Eur J Gastroenterol Hepatol 8 (10):951-955,1996.
80. Mikami T, Meguro A, Teshigawara T, Takeuchi M, Uemoto R, Kawagoe T, Nomura E, Asukata Y, Ishioka M, Iwasaki M, Fukagawa K, Konomi K, Shimazaki J, Nishida T, Mizuki N. Interleukin 1 beta promoter polymorphism is associated with keratoconus in a Japanese population. Mol Vis 19:845-851,2013.
81. Chen H, Wilkins LM, Aziz N, Cannings C, Wyllie DH, Bingle C, Rogus J, Beck JD, Offenbacher S, Cork MJ, Rafie-Kolpin M, Hsieh CM, Kornman KS, Duff GW. Single nucleotide polymorphisms in the human interleukin-1B gene affect transcription according to haplotype context. Hum Mol Genet 15 (4):519-529. doi:10.1093/hmg/ddi469,2006.
82. Gabay C, Lamacchia C, Palmer G. IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol 6 (4):232-241. doi:10.1038/nrrheum.2010.4,2010.
83. Watanabe T, Ajioka Y, Mitsuyama K, Watanabe K, Hanai H, Nakase H, Kunisaki R, Matsuda K, Iwakiri R, Hida N, Tanaka S, Takeuchi Y, Ohtsuka K, Murakami K, Kobayashi K, Iwao Y, Nagahori M, Iizuka B, Hata K, Igarashi M, Hirata I, Kudo SE, Matsumoto T, Ueno F, Watanabe G, Ikegami M, Ito Y, Oba K, Inoue E, Tomotsugu N, Takebayashi T, Sugihara K, Suzuki Y, Watanabe M, Hibi T. Comparison of Targeted vs Random Biopsies for Surveillance of Ulcerative Colitis-Associated Colorectal Cancer. Gastroenterology 151 (6):1122-1130. doi:10.1053/j.gastro.2016.08.002,2016.